The subscription price for the TO3 warrants was set at SEK 0.13, determined prior to the issuance of new shares in the rights issue completed in November 2024. The warrants were available for subscription until 17 April 2024 and could be exercised from 17 February 2025 to 3 March 2025, with the last day of trading on 27 February 2025.

As the subscription price exceeded the prevailing market price, no subscriptions were received. Consequently, the anticipated increase in share capital and potential dilution for existing shareholders will not take place.

Spermosens recently secured an investment of SEK 10.8 million through a directed share issue from a consortium of American and European strategic investors, as communicated on 4 March 2025. This investment, which does not involve the issuance of any warrants, ensures funding for the Company until the second half of 2026, when Spermosens expects to achieve cash flow positivity, primarily through revenue generated from license agreements with established partners in the global Assisted Reproductive Technology (ART) market.

Furthermore, the upcoming TO5 warrants will be exercisable from 2 June 2025 to 16 June 2025, while the TO6 warrants will be exercisable from 16 November 2026 to 27 November 2026.

For further information, please contact:
Tore Duvold, CEO
Email: info@spermosens.com

Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checkedproduct aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com

Spermosens grundades 2018 och utvecklar medicintekniska produkter för manlig infertilitet för att individualisera och anpassa In Vitro Fertiliserings-behandlingar. Teknologin grundar sig på en oberoende forskargrupps upptäckt av det s k JUNO-proteinet i mänskliga äggceller 2018. Spermosens första patentansökta produkt består huvudsakligen av två komponenter; ett mätinstrument med tillhörande programvara, samt engångschip. Mätinstrumentet analyserar spermierna som applicerats på chipen och utläser om de kan binda till äggcellen via JUNO-proteinet.